Evropska unija - estonščina - EMA (European Medicines Agency)

roche registration gmbh - ocrelizumab - hulgiskleroos - immunosupressandid - täiskasvanud patsientidel, kellel on kliinilistes või pildistamisfunktsioonides määratletud aktiivne haigus koos hulgiskleroosiga (rms). ravi täiskasvanud patsientidel varajases primaarne progresseeruv sclerosis multiplex (ppms) seoses haiguse kestus ja puude, ja koos pildistamine funktsioone iseloomulik põletikuline aktiivsus.

Evropska unija - estonščina - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - sclerosis multiplex, relapsing-remitting - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Evropska unija - estonščina - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - sclerosis multiplex, relapsing-remitting - immunosupressandid - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Evropska unija - estonščina - EMA (European Medicines Agency)

mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropska unija - estonščina - EMA (European Medicines Agency)

mylan ireland limited - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Evropska unija - estonščina - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Estonija - estonščina - Ravimiamet

accord healthcare b.v. - tsüklofosfamiid - süste-/infusioonilahuse pulber - 1000mg 1tk

Estonija - estonščina - Ravimiamet

accord healthcare b.v. - tsüklofosfamiid - süste-/infusioonilahuse pulber - 500mg 1tk

Estonija - estonščina - Ravimiamet

virbac - permetriin+fiproniil - täpilahus - 1200mg+134mg 2.2ml 2.2ml 60tk; 1200mg+134mg 2.2ml 2.2ml 24tk; 1200mg+134mg 2.2ml 2.2ml 4tk

Estonija - estonščina - Ravimiamet

boehringer ingelheim animal health france - permetriin+fiproniil - täpilahus - 1009,6mg+135,2mg 2ml 2ml 3tk; 1009,6mg+135,2mg 2ml 2ml 1tk; 1009,6mg+135,2mg 2ml 2ml 6tk